Effects of metrifonate on memory impairment and cholinergic dysfunction in rats

Akio Itoh, Atsumi Nitta, Yuki Katono, Miho Usui, Kazumasa Naruhashi, Ryuichi Iida, Takaaki Hasegawa, Toshitaka Nabeshima

Research output: Contribution to journalArticle

39 Citations (Scopus)

Abstract

Metrifonate is an organophosphorous compound that has been used in the treatment of schistosomiasis. In this study, we investigated the effects of metrifonate on the impairment of learning and on central cholinergic dysfunction in scopolamine-treated and basal forebrain-lesioned rats. Oral administration of metrifonate (5.0-15.0 mg/kg) ameliorated the scopolamine- and basal forebrain lesion-induced learning impairment in the water maze and passive avoidance tasks. Metrifonate (50 and 100 mg/kg) also significantly increased extracellular acetylcholine levels but decreased choline levels in the cerebral cortex of the basal forebrain-lesioned rats. The basal forebrain lesion decreased the cholinesterase activity in the cerebral cortex, and metrifonate (100 mg/kg) further reduced the cholinesterase activity. However, cholinesterase inhibition was not observed at the dose that ameliorated learning impairments. These results indicated that metrifonate ameliorated the impairment of learning in both scopolamine-treated and basal forebrain-lesioned rats by not only increasing extracellular acetylcholine levels by inhibiting cholinesterase, but also by undefined other mechanism(s). This finding suggests the usefulness of metrifonate for the therapy of Alzheimer's disease.

Original languageEnglish
Pages (from-to)11-19
Number of pages9
JournalEuropean Journal of Pharmacology
Volume322
Issue number1
DOIs
Publication statusPublished - 12-03-1997

Fingerprint

Trichlorfon
Cholinergic Agents
Cholinesterases
Scopolamine Hydrobromide
Learning
Cerebral Cortex
Acetylcholine
Schistosomiasis
Choline
Oral Administration
Alzheimer Disease
Basal Forebrain
Water
Therapeutics

All Science Journal Classification (ASJC) codes

  • Pharmacology

Cite this

Itoh, Akio ; Nitta, Atsumi ; Katono, Yuki ; Usui, Miho ; Naruhashi, Kazumasa ; Iida, Ryuichi ; Hasegawa, Takaaki ; Nabeshima, Toshitaka. / Effects of metrifonate on memory impairment and cholinergic dysfunction in rats. In: European Journal of Pharmacology. 1997 ; Vol. 322, No. 1. pp. 11-19.
@article{92e8409fcb844326931431b5b4f236c3,
title = "Effects of metrifonate on memory impairment and cholinergic dysfunction in rats",
abstract = "Metrifonate is an organophosphorous compound that has been used in the treatment of schistosomiasis. In this study, we investigated the effects of metrifonate on the impairment of learning and on central cholinergic dysfunction in scopolamine-treated and basal forebrain-lesioned rats. Oral administration of metrifonate (5.0-15.0 mg/kg) ameliorated the scopolamine- and basal forebrain lesion-induced learning impairment in the water maze and passive avoidance tasks. Metrifonate (50 and 100 mg/kg) also significantly increased extracellular acetylcholine levels but decreased choline levels in the cerebral cortex of the basal forebrain-lesioned rats. The basal forebrain lesion decreased the cholinesterase activity in the cerebral cortex, and metrifonate (100 mg/kg) further reduced the cholinesterase activity. However, cholinesterase inhibition was not observed at the dose that ameliorated learning impairments. These results indicated that metrifonate ameliorated the impairment of learning in both scopolamine-treated and basal forebrain-lesioned rats by not only increasing extracellular acetylcholine levels by inhibiting cholinesterase, but also by undefined other mechanism(s). This finding suggests the usefulness of metrifonate for the therapy of Alzheimer's disease.",
author = "Akio Itoh and Atsumi Nitta and Yuki Katono and Miho Usui and Kazumasa Naruhashi and Ryuichi Iida and Takaaki Hasegawa and Toshitaka Nabeshima",
year = "1997",
month = "3",
day = "12",
doi = "10.1016/S0014-2999(96)00977-6",
language = "English",
volume = "322",
pages = "11--19",
journal = "European Journal of Pharmacology",
issn = "0014-2999",
publisher = "Elsevier",
number = "1",

}

Itoh, A, Nitta, A, Katono, Y, Usui, M, Naruhashi, K, Iida, R, Hasegawa, T & Nabeshima, T 1997, 'Effects of metrifonate on memory impairment and cholinergic dysfunction in rats', European Journal of Pharmacology, vol. 322, no. 1, pp. 11-19. https://doi.org/10.1016/S0014-2999(96)00977-6

Effects of metrifonate on memory impairment and cholinergic dysfunction in rats. / Itoh, Akio; Nitta, Atsumi; Katono, Yuki; Usui, Miho; Naruhashi, Kazumasa; Iida, Ryuichi; Hasegawa, Takaaki; Nabeshima, Toshitaka.

In: European Journal of Pharmacology, Vol. 322, No. 1, 12.03.1997, p. 11-19.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Effects of metrifonate on memory impairment and cholinergic dysfunction in rats

AU - Itoh, Akio

AU - Nitta, Atsumi

AU - Katono, Yuki

AU - Usui, Miho

AU - Naruhashi, Kazumasa

AU - Iida, Ryuichi

AU - Hasegawa, Takaaki

AU - Nabeshima, Toshitaka

PY - 1997/3/12

Y1 - 1997/3/12

N2 - Metrifonate is an organophosphorous compound that has been used in the treatment of schistosomiasis. In this study, we investigated the effects of metrifonate on the impairment of learning and on central cholinergic dysfunction in scopolamine-treated and basal forebrain-lesioned rats. Oral administration of metrifonate (5.0-15.0 mg/kg) ameliorated the scopolamine- and basal forebrain lesion-induced learning impairment in the water maze and passive avoidance tasks. Metrifonate (50 and 100 mg/kg) also significantly increased extracellular acetylcholine levels but decreased choline levels in the cerebral cortex of the basal forebrain-lesioned rats. The basal forebrain lesion decreased the cholinesterase activity in the cerebral cortex, and metrifonate (100 mg/kg) further reduced the cholinesterase activity. However, cholinesterase inhibition was not observed at the dose that ameliorated learning impairments. These results indicated that metrifonate ameliorated the impairment of learning in both scopolamine-treated and basal forebrain-lesioned rats by not only increasing extracellular acetylcholine levels by inhibiting cholinesterase, but also by undefined other mechanism(s). This finding suggests the usefulness of metrifonate for the therapy of Alzheimer's disease.

AB - Metrifonate is an organophosphorous compound that has been used in the treatment of schistosomiasis. In this study, we investigated the effects of metrifonate on the impairment of learning and on central cholinergic dysfunction in scopolamine-treated and basal forebrain-lesioned rats. Oral administration of metrifonate (5.0-15.0 mg/kg) ameliorated the scopolamine- and basal forebrain lesion-induced learning impairment in the water maze and passive avoidance tasks. Metrifonate (50 and 100 mg/kg) also significantly increased extracellular acetylcholine levels but decreased choline levels in the cerebral cortex of the basal forebrain-lesioned rats. The basal forebrain lesion decreased the cholinesterase activity in the cerebral cortex, and metrifonate (100 mg/kg) further reduced the cholinesterase activity. However, cholinesterase inhibition was not observed at the dose that ameliorated learning impairments. These results indicated that metrifonate ameliorated the impairment of learning in both scopolamine-treated and basal forebrain-lesioned rats by not only increasing extracellular acetylcholine levels by inhibiting cholinesterase, but also by undefined other mechanism(s). This finding suggests the usefulness of metrifonate for the therapy of Alzheimer's disease.

UR - http://www.scopus.com/inward/record.url?scp=0030931020&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0030931020&partnerID=8YFLogxK

U2 - 10.1016/S0014-2999(96)00977-6

DO - 10.1016/S0014-2999(96)00977-6

M3 - Article

C2 - 9088864

AN - SCOPUS:0030931020

VL - 322

SP - 11

EP - 19

JO - European Journal of Pharmacology

JF - European Journal of Pharmacology

SN - 0014-2999

IS - 1

ER -